11 Best GLP-1 and Weight Loss Stocks to Invest in

7. Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders: 60

Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to 10–16% (from 16-24%) and revenue growth projections to 8-14% (from 13-21%) at constant currency rates (CER) in its 2025 full-year guidance. The projection shows lower demand for Wegovy® and Ozempic® in the United States and a few foreign markets, despite an 18% sales and 29% profit increase in H1 2025.

The downgrading is attributed to the decreased adoption of Wegovy, resulting from continued sales of compounded GLP-1s, even after the FDA’s mass compounding grace period expired in May. The weekly prescriptions through NovoCare® Pharmacy are 11,000, with an additional 20,000 in retail cash channels. Novo Nordisk A/S (NYSE:NVO) is taking legal action and extending its telehealth and pharmaceutical collaborations. Growing competition is another factor putting pressure on Ozempic® sales in the US. Furthermore, adoption in global markets for obesity has been modest. Novo Nordisk A/S (NYSE:NVO) anticipates a DKK 3 billion net financial gain from currency hedging and DKK 35-45 billion in free cash flow. Full H1 financials will be available on August 6, 2025. It is among the Best Weight Loss Stocks.